Simfibrate
Clinical data | |
---|---|
Trade names | Cholesolvin |
Other names | 3-{[2-(4-Chlorophenoxy)-2-methylpropanoyl]oxy}propyl 2-(4-chlorophenoxy)-2-methylpropanoate |
ATC code | |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.035.438 |
Chemical and physical data | |
Formula | C23H26Cl2O6 |
Molar mass | 469.36 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
Simfibrate (JAN/INN; trade name Cholesolvin) is a fibrate that has been used for the treatment of hyperlipidemia.[1][2] The substance is a double ester of clofibric acid with 1,3-propanediol which is cleaved in the body to one molecule of 1,3-propanediol and two molecules of clofibric acid which is the true lipid-lowering agent.
References
- ↑ Verma N (2016). "Introduction to Hyperlipidemia and its Treatment: A Review". International Journal of Current Pharmaceutical Research. 9: 6. doi:10.22159/ijcpr.2017v9i1.16616.
- ↑ Olsson AG, Orö L, Rössner S (1974). "Clinical and metabolic effects of pentaerythritol tetranicotinate in combination with cholesolvin or clofibrate". Atherosclerosis. 19 (3): 407–15. doi:10.1016/S0021-9150(74)80005-5. PMID 4364073.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.